Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.7, 2004-01, pp. : 453-468

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline

By Halbreich Uriel Kahn Linda S

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. : 2065-2078

Informa Healthcare

Access to resources Recommend Favorite

Premenstrual dysphoric disorder: is it simply PMS?

By Endicott J.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 259-259

Elsevier

Access to resources Recommend Favorite

Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions

By Ross Lori E Steiner Meir

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 10, 2003-10 ,pp. : 1491-1499

Informa Healthcare

Access to resources Recommend Favorite

Duloxetine for premenstrual dysphoric disorder: a pilot study

By Mazza Marianna Harnic Desiree Catalano Valeria Janiri Luigi Bria Pietro

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 4, 2008-03 ,pp. : 517-521

Informa Healthcare

Access to resources Recommend Favorite

Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder

By Yonkers Kimberly A Pearlstein Teri

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 979-991

Informa Healthcare

Access to resources Recommend Favorite